Description
Epcoritamab is indicated for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified, including diffuse large B-cell lymphoma arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy.
In June 2024, the US Food and Drug Administration (FDA) expanded the indication to include the treatment of adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
The US Food and Drug Administration (FDA) prescribing information includes a boxed warning for serious or fatal cytokine release syndrome and immune effector cell-associated neurotoxicity. Warnings and precautions include serious infections and cytopenias.
EPKINLY (epcoritamab-bysp) injection, for subcutaneous use Initial U.S. Approval: 2023.
See full prescribing information: Click Here
Get Access To Epkinly (Epcoritamab-BYSP) Injection In India On Request
Brand Name “Epkinly” or Generic Name “Epcoritamab-BYSP” can be imported for personal use under “Named Patient Program” treatment in Delhi, Kolkata, Surat, Jaipur, Noida, Gurgaon (Gurugram), Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura and Sikkim, Noida, Kanpur, Lucknow, Dehradun, Shimla, Ahmedabad, Jodhpur, Mumbai, Jaipur, Aurangabad, Pune, Bangalore, Hyderabad, Chennai, Visakhapatnam, Coimbatore, Andhra Pradesh, Karnataka, Kerala, Lakshadweep, Puducherry, Tamil Nadu, Telangana, India. Contact us at support@southdelhipharma.net, southdelhipharma@gmail.com or you can call at 9891296838 or WhatsApp at 9891296838
